Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer.

Jeitany M, Leroy C, Tosti P, Lafitte M, Le Guet J, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, El Messaoudi S, Otandault A, Canterel-Thouennon L, Busson M, Thierry AR, Martineau P, Pannequin J, Roche S, Sirvent A.

EMBO Mol Med. 2018 Feb 9. pii: e7918. doi: 10.15252/emmm.201707918. [Epub ahead of print]

2.

Opposite effects of GCN5 and PCAF knockdowns on the alternative mechanism of telomere maintenance.

Jeitany M, Bakhos-Douaihy D, Silvestre DC, Pineda JR, Ugolin N, Moussa A, Gauthier LR, Busso D, Junier MP, Chneiweiss H, Chevillard S, Desmaze C, Boussin FD.

Oncotarget. 2017 Apr 18;8(16):26269-26280. doi: 10.18632/oncotarget.15447.

3.

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou L.

Science. 2015 Jan 16;347(6219):273-7. doi: 10.1126/science.1257216.

4.

A preclinical mouse model of glioma with an alternative mechanism of telomere maintenance (ALT).

Jeitany M, Pineda JR, Liu Q, Porreca RM, Hoffschir F, Desmaze C, Silvestre DC, Mailliet P, Junier MP, Londoño-Vallejo A, Ségal-Bendirdjian E, Chneiweiss H, Boussin FD.

Int J Cancer. 2015 Apr 1;136(7):1546-58. doi: 10.1002/ijc.29171. Epub 2014 Sep 11.

Supplemental Content

Loading ...
Support Center